title: The yeast product Milmed enhances the effect of physical exercise on motor performance and dopamine neurochemistry recovery in MPTP-lesioned mice.
abstract: Both clinical and laboratory studies have demonstrated that different types of physical exercise may alleviate Parkinsonism yet evidence for complete restoration of motor function and biomarker integrity are difficult to identify. MPTP (1 × 30 mg/kg, s.c., 4 groups) or saline (vehicle 1 × 5 ml/kg, s.c., 1 group) were administered in a single dose regime over three consecutive weeks on Fridays. Three MPTP groups were given four 30-min periods/week (Mondays to Thursdays), of these two groups, MPTP + Exer + M(i) and MPTP + Exer + M(ii); the former were introduced to exercise and Milmed (oral injection) on the week following the 1st MPTP injection and the latter on the Monday prior to the 1st injection of MPTP onwards. One MPTP group, MPTP + Exer, was given access to exercise (running wheels) from the week following the 1st MPTP injection onwards. The fourth MPTP group, MPTP-NoEx, and the Vehicle group were only given access to exercise on a single day each week (Wednesdays, exercise test) from the week following the 1st MPTP injection onwards. The exercise/exercise + Milmed regime was maintained for a further 9 weeks. It was observed that exercise by itself ameliorated MPTP-induced deficits regarding motor function and dopamine loss only partially whereas in the groups combining exercise with twice weekly dosages of Milmed the MPTP-induced deficits were abolished by the 10th week of the intervention. The three main conclusions that were drawn from correlational analyses of individual mice were: (i) that DA integrity was observed to be a direct function of ability to express running exercise in a treadmill wheel-running arrangement, and (ii) that DA integrity was observed to be a direct function of the capacity for motor performance as measured by spontaneous motor activity and subthreshold L-Dopa (5 mg/kg) induced activity in the motor activity test chambers, and (iii) that the extent to which running exercise in a running wheel was predictive of later motor performance in the activity test chambers was highly convincing.
authors.affiliation: Department of Psychology, University of Gothenburg, Box 500, 430 50, Göteburg, Sweden. trevor.archer@psy.gu.se
authors.forename: Trevor
authors.initials: T
authors.lastname: Archer
authors.forename: Anders
authors.initials: A
authors.lastname: Fredriksson
mesh_terms: D000818:Animals; D004298:Dopamine / Q000378:metabolism*; D020267:MPTP Poisoning / Q000139:chemically induced / Q000378:metabolism* / Q000628:therapy*; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D009043:Motor Activity / Q000187:drug effects / Q000502:physiology*; D010805:Physical Conditioning, Animal / Q000379:methods / Q000502:physiology*; D012441:Saccharomyces cerevisiae / Q000378:metabolism*; D016896:Treatment Outcome; D015003:Yeasts / Q000378:metabolism
chemical_list: D004298:Dopamine
references.citation: Science. 2003 Dec 5;302(5651):1772-5
references.pmid: 14657500
references.citation: J Neural Transm Park Dis Dement Sect. 1994;7(2):123-32
references.pmid: 7710664
references.citation: J Alzheimers Dis. 2010;19(1):191-210
references.pmid: 20061638
references.citation: Behav Brain Res. 2003 Feb 17;139(1-2):31-46
references.pmid: 12642174
references.citation: J Neurosci Res. 2004 Aug 1;77(3):378-90
references.pmid: 15248294
references.citation: J Med Chem. 1995 Jan 6;38(1):150-60
references.pmid: 7530773
references.citation: Braz J Med Biol Res. 2013 Jan;46(1):14-20
references.pmid: 23314343
references.citation: Acta Neurol Scand. 2011 Feb;123(2):73-84
references.pmid: 21108623
references.citation: Nat Protoc. 2007;2(1):141-51
references.pmid: 17401348
references.citation: Pharmacol Toxicol. 1990 Oct;67(4):295-301
references.pmid: 2077520
references.citation: Life Sci. 1994;54(4):245-52
references.pmid: 8289584
references.citation: Phys Rev E Stat Nonlin Soft Matter Phys. 2011 Jul;84(1 Pt 1):011926
references.pmid: 21867232
references.citation: Arch Phys Med Rehabil. 1986 Oct;67(10):741-5
references.pmid: 3767624
references.citation: J Neural Transm (Vienna). 1999;106(3-4):283-300
references.pmid: 10392537
references.citation: Behav Brain Res. 2010 Dec 1;213(2):253-62
references.pmid: 20472000
references.citation: Handb Exp Pharmacol. 2011;206:241-55
references.pmid: 21879453
references.citation: FEMS Yeast Res. 2010 Dec;10(8):970-9
references.pmid: 20579105
references.citation: J Neurosci Res. 2010 Feb 15;88(3):650-68
references.pmid: 19746427
references.citation: Pharmacol Biochem Behav. 2011 Oct;99(4):704-11
references.pmid: 21741988
references.citation: J Alzheimers Dis. 2012;32(2):243-66
references.pmid: 22810103
references.citation: JAMA Neurol. 2013 Feb;70(2):183-90
references.pmid: 23128427
references.citation: Phys Ther Rev. 1956 Mar;36(3):176-8
references.pmid: 13297544
references.citation: Prog Neuropsychopharmacol Biol Psychiatry. 1988;12(2-3):345-54
references.pmid: 3260386
references.citation: J Appl Physiol (1985). 2006 Dec;101(6):1776-82
references.pmid: 16959909
references.citation: J Neural Transm (Vienna). 2011 Mar;118(3):407-20
references.pmid: 20852902
references.citation: Mol Chem Neuropathol. 1989 Jun;10(3):171-83
references.pmid: 2669769
references.citation: Nat Med. 2007 Dec;13(12):1476-82
references.pmid: 18059283
references.citation: Life Sci. 1985 Jan 21;36(3):201-6
references.pmid: 2857048
references.citation: Naunyn Schmiedebergs Arch Pharmacol. 1985 Oct;331(1):1-6
references.pmid: 3877877
references.citation: Mov Disord. 2013 Aug;28(9):1230-40
references.pmid: 23536417
references.citation: Kathmandu Univ Med J (KUMJ). 2012 Apr-Jun;10(38):77-82
references.pmid: 23132482
references.citation: Eur J Pharmacol. 1991 Jul 9;199(3):367-70
references.pmid: 1833212
references.citation: Pharmacol Biochem Behav. 2013 Mar;104:113-8
references.pmid: 23290938
references.citation: J Neural Transm (Vienna). 2003 Feb;110(2):183-200
references.pmid: 12589577
references.citation: Cell Cycle. 2010 Oct;9(20):4046
references.pmid: 20980804
references.citation: Trends Biochem Sci. 2010 Mar;35(3):135-44
references.pmid: 19926288
references.citation: FEMS Yeast Res. 2008 Feb;8(1):122-31
references.pmid: 17727659
references.citation: Neurotox Res. 2010 Nov;18(3-4):313-27
references.pmid: 20300909
references.citation: Physiol Behav. 2008 Mar 18;93(4-5):1044-54
references.pmid: 18304593
references.citation: Neurosci Behav Physiol. 1998 Jan-Feb;28(1):26-30
references.pmid: 9513974
references.citation: FEMS Yeast Res. 2010 Dec;10(8):1046-59
references.pmid: 20977625
references.citation: Brain Res. 1990 Oct 1;528(2):181-8
references.pmid: 2271921
references.citation: Neuropsychopharmacology. 2006 Dec;31(12):2627-38
references.pmid: 16421512
references.citation: J Neurochem. 2013 Nov;127(4):438-52
references.pmid: 23600759
references.citation: Curr Opin Microbiol. 2010 Jun;13(3):382-8
references.pmid: 20439164
references.citation: Neuroscience. 2007 Feb 9;144(3):1141-51
references.pmid: 17157992
references.citation: J Neural Transm (Vienna). 2006 Sep;113(9):1119-29
references.pmid: 16362627
references.citation: Neurobiol Dis. 2008 Nov;32(2):319-27
references.pmid: 18718537
references.citation: Neurodegeneration. 1995 Sep;4(3):257-69
references.pmid: 8581558
references.citation: Neurotox Res. 2012 Feb;21(2):210-21
references.pmid: 21830164
references.citation: Neuroscience. 2012 Dec 27;227:305-12
references.pmid: 23041759
references.citation: Eur Neurol. 1987;26 Suppl 1:16-23
references.pmid: 2884111
references.citation: J Neurosci. 2007 May 16;27(20):5291-300
references.pmid: 17507552
references.citation: Mov Disord. 2010;25 Suppl 1:S141-5
references.pmid: 20187247
references.citation: Cell Cycle. 2012 Nov 15;11(22):4135-46
references.pmid: 22983125
references.citation: Psychopharmacology (Berl). 1986;88(2):141-6
references.pmid: 3081924
references.citation: J Neurosci Nurs. 1989 Jun;21(3):180-4
references.pmid: 2525159
references.citation: Eur J Neurosci. 2011 Apr;33(7):1264-74
references.pmid: 21375602